Peter Kolchinsky portfolio
RA Capital Management · Biotechnology specialist
RA Capital Management's 13F filing for Q2 2026, filed with the SEC on August 14, 2026, reports $11.5B across 84 US-listed positions. The largest holding is ASND at 23.8% of the portfolio; the ten largest make up 60%. The largest buy last quarter was PBLS, a new position ($791.9M).
Key facts
- 13F portfolio value
- $11.5BQ2 2026
- Positions
- 84
- Largest holding
- ASND 23.8%
- Top 10 share
- 60%
- New positions
- 16since Q1 2026
- Sold out
- 17
- Filed
- Aug 14, 2026
- Next 13F due
- Nov 16, 2026Q3 2026
Holdings as of (Q2 2026), filed with the SEC on . Changes are measured against the filing for Mar 31, 2026. Source: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824).
Prices as of .
Compared with Q1 2026, Peter Kolchinsky opened 16 new positions (PBLS, COAG, ABVX…), added to 10, trimmed 10, sold out of 17 (DNTH, PRAX, SRPT…).
By sector, Health Care is the largest at 43% of the reported portfolio, followed by Technology at 0%; 57% is in securities with no sector on file.
26 of the 84 positions listed have been in every one of the last 9 quarterly filings.
Peter Kolchinsky top holdings: stocks in the Q2 2026 13F
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Price now | Since period end | Held | Last quarter |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ascendis Pharma A/SASND | Health Care | 23.8% | $2.7B | 10.28M | $266.72 | $267.09 | 0.1% up | 9+ qtrs | — |
| 2 | Parabilis Medicines IncPBLS | — | 6.88% | $791.9M | 28.93M | $27.37 | $28.17 | 2.9% up | 1 qtr | New |
| 3 | Rhythm Pharmaceuticals IncRYTM | Health Care | 6.43% | $740.2M | 6.67M | $111.03 | $113.28 | 2.0% up | 9+ qtrs | No change |
| 4 | Vaxcyte IncPCVX | Health Care | 5.80% | $667M | 11.47M | $58.13 | $59.98 | 3.2% up | 9+ qtrs | No change |
| 5 | Sionna Therapeutics IncSION | — | 3.79% | $435.7M | 9.91M | $43.99 | $3.07 | 93.0% down | 6 qtrs | No change |
| 6 | Tyra Biosciences IncTYRA | — | 3.39% | $389.6M | 12.2M | $31.94 | $19.88 | 37.8% down | 9+ qtrs | No change |
| 7 | Edgewise Therapeutics IncEWTX | Health Care | 2.96% | $341M | 8.39M | $40.63 | $42.07 | 3.5% up | 9+ qtrs | ▼ Reduced 20% |
| 8 | Newamsterdam Pharma CompanyNAMS | — | 2.81% | $323.7M | 9.55M | $33.89 | $19.39 | 42.8% down | 9+ qtrs | No change |
| 9 | Hemab Therapeutics HoldingsCOAG | — | 2.49% | $286.8M | 7.81M | $36.73 | $38.50 | 4.8% up | 1 qtr | New |
| 10 | Septerna IncSEPN | — | 2.04% | $234.3M | 7M | $33.49 | $39.44 | 17.8% up | 7 qtrs | No change |
| 11 | Bicara Therapeutics IncBCAX | — | 1.87% | $215.4M | 7.26M | $29.69 | $9.62 | 67.6% down | 8 qtrs | No change |
| 12 | Mineralys Therapeutics IncMLYS | — | 1.80% | $207.6M | 7.69M | $26.98 | $14.53 | 46.1% down | 9+ qtrs | No change |
| 13 | GH Research PLCGHRS | — | 1.78% | $205.3M | 7.64M | $26.88 | $17.76 | 33.9% down | 9+ qtrs | ▼ Reduced 0.5% |
| 14 | Disc Medicine IncIRON | — | 1.56% | $179.2M | 2.45M | $73.14 | $76.62 | 4.8% up | 6 qtrs | No change |
| 15 | Spyglass Pharma IncSGP | — | 1.55% | $178.6M | 8.02M | $22.26 | $31.03 | 39.4% up | 2 qtrs | No change |
| 16 | Artiva Biotherapeutics IncARTV | — | 1.51% | $174.2M | 17.96M | $9.70 | $3.90 | 59.8% down | 8 qtrs | ▲ Added 82% |
| 17 | Janux Therapeutics IncJANX | — | 1.49% | $171.9M | 11.19M | $15.36 | $10.77 | 29.9% down | 9+ qtrs | No change |
| 18 | Taysha Gene Therapies IncTSHA | — | 1.39% | $160.4M | 23.56M | $6.81 | $4.03 | 40.8% down | 9+ qtrs | No change |
| 19 | BioCryst Pharmaceuticals IncBCRX | — | 1.38% | $158.3M | 15.83M | $10.00 | $7.46 | 25.4% down | 3 qtrs | No change |
| 20 | Wave Life Sciences LtdWVE | — | 1.36% | $156.7M | 26.98M | $5.81 | $2.91 | 49.9% down | 9+ qtrs | No change |
| 21 | Nuvalent Incno ticker on file | — | 1.34% | $153.9M | 1.25M | $123.50 | — | — | 4 qtrs | ▼ Reduced 51% |
| 22 | Abivax SAABVX · ADR | Health Care | 1.31% | $150.9M | 1.13M | $133.26 | $83.02 | 37.7% down | 1 qtr | New |
| 23 | Oruka Therapeutics IncORKA | Health Care | 1.29% | $148M | 1.55M | $95.17 | $96.48 | 1.4% up | 1 qtr | New |
| 24 | Climb Bio IncCLYM | — | 1.28% | $147.4M | 11.3M | $13.04 | $9.64 | 26.1% down | 9+ qtrs | No change |
| 25 | Solid Biosciences IncSLDB | — | 1.05% | $120.2M | 12.04M | $9.99 | $6.36 | 36.3% down | 9+ qtrs | ▲ Added 29% |
| 26 | Zai Lab LtdZLAB · ADR | — | 0.95% | $109.1M | 5.74M | $19.00 | $23.46 | 23.5% up | 2 qtrs | ▲ Added 0.6% |
| 27 | Ars Pharmaceuticals IncSPRY | — | 0.76% | $87M | 10.86M | $8.01 | $3.73 | 53.5% down | 9+ qtrs | No change |
| 28 | Xencor IncXNCR | — | 0.74% | $84.9M | 5.27M | $16.10 | $34.71 | 115.6% up | 2 qtrs | ▲ Added 7.7% |
| 29 | Jade Biosciences IncJBIO | — | 0.71% | $81.6M | 3.67M | $22.22 | $15.07 | 32.2% down | 5 qtrs | No change |
| 30 | Intellia Therapeutics IncNTLA | — | 0.67% | $76.6M | 4.53M | $16.92 | $9.86 | 41.8% down | 1 qtr | New |
| 31 | LB Pharmaceuticals IncLBRX | — | 0.62% | $71.7M | 2.21M | $32.46 | $40.26 | 24.0% up | 4 qtrs | No change |
| 32 | Definium Therapeutics IncDFTX | Health Care | 0.61% | $70.6M | 1.5M | $47.04 | $29.27 | 37.8% down | 1 qtr | New |
| 33 | Aclaris Therapeutics IncACRS | — | 0.59% | $67.3M | 12.72M | $5.29 | $3.52 | 33.6% down | 2 qtrs | ▲ Added 87% |
| 34 | 4D Molecular TherapeuticsFDMT | — | 0.58% | $67.2M | 5.05M | $13.30 | $10.77 | 19.0% down | 9+ qtrs | No change |
| 35 | Sana Biotechnology IncSANA | — | 0.57% | $65.4M | 18.75M | $3.49 | $1.89 | 46.0% down | 1 qtr | New |
| 36 | Damora Therapeutics IncDMRA | — | 0.54% | $62.4M | 2.4M | $26.01 | $22.36 | 14.1% down | 2 qtrs | ▲ Added 0.02% |
| 37 | Monopar Therapeutics IncMNPR | — | 0.54% | $61.8M | 667.21K | $92.59 | $70.85 | 23.5% down | 7 qtrs | No change |
| 38 | Acumen Pharmaceuticals IncABOS | — | 0.49% | $56.1M | 20.99M | $2.67 | $0.2110 | 92.1% down | 9+ qtrs | No change |
| 39 | Geron CorpGERN | — | 0.48% | $54.8M | 42.81M | $1.28 | $0.9777 | 23.6% down | 9+ qtrs | ▼ Reduced 33% |
| 40 | Rezolute IncRZLT | — | 0.43% | $49.1M | 9.45M | $5.20 | $3.79 | 27.1% down | 3 qtrs | ▲ Added 2.9% |
| 41 | Evommune IncEVMN | — | 0.40% | $46.4M | 3.49M | $13.29 | $7.00 | 47.4% down | 3 qtrs | No change |
| 42 | Vor Biopharma IncVOR | — | 0.38% | $44.2M | 2.4M | $18.41 | $18.49 | 0.4% up | 9+ qtrs | ▼ Reduced 56% |
| 43 | Century Therapeutics IncIPSC | — | 0.38% | $43.5M | 17.75M | $2.45 | $1.49 | 39.2% down | 2 qtrs | No change |
| 44 | Aktis Oncology IncAKTS | — | 0.37% | $42.4M | 1.31M | $32.23 | $16.20 | 49.7% down | 2 qtrs | ▼ Reduced 13% |
| 45 | Bioage Labs IncBIOA | — | 0.36% | $41M | 1.67M | $24.51 | $5.18 | 78.9% down | 2 qtrs | ▲ Added 1.3% |
| 46 | C4 Therapeutics IncCCCC | — | 0.33% | $37.4M | 8M | $4.67 | $2.53 | 45.8% down | 3 qtrs | No change |
| 47 | Mirum Pharmaceuticals IncMIRM | Health Care | 0.32% | $37.3M | 318.55K | $117.07 | $90.59 | 22.6% down | 2 qtrs | No change |
| 48 | Capricor Therapeutics IncCAPR | — | 0.32% | $36.3M | 1.51M | $24.08 | $8.82 | 63.4% down | 3 qtrs | No change |
| 49 | Pepgen IncPEPG | — | 0.31% | $36.1M | 20.06M | $1.80 | $3.72 | 106.4% up | 9+ qtrs | No change |
| 50 | Prelude Therapeutics IncPRLD | — | 0.30% | $34.5M | 6.48M | $5.33 | $3.33 | 37.5% down | 1 qtr | New |
| 51 | Nkarta IncNKTX | — | 0.27% | $30.6M | 10.81M | $2.83 | $1.26 | 55.5% down | 9+ qtrs | No change |
| 52 | Q32 Bio IncQTTB | — | 0.26% | $29.7M | 2.33M | $12.74 | $8.58 | 32.7% down | 1 qtr | New |
| 53 | Anteris Technologies GlobalAVR | — | 0.26% | $29.6M | 3M | $9.85 | $5.58 | 43.4% down | 2 qtrs | No change |
| 54 | Editas Medicine IncEDIT | — | 0.25% | $28.8M | 8.89M | $3.24 | $1.89 | 41.8% down | 1 qtr | New |
| 55 | Ovid Therapeutics IncOVID | — | 0.25% | $28.2M | 10.5M | $2.69 | $2.28 | 15.4% down | 3 qtrs | ▼ Reduced 2.0% |
| 56 | Assembly Biosciences IncASMB | — | 0.24% | $28M | 1.02M | $27.48 | $22.33 | 18.7% down | 4 qtrs | No change |
| 57 | Alx Oncology Holdings IncALXO | — | 0.23% | $26.9M | 13.01M | $2.07 | $1.03 | 50.5% down | 2 qtrs | No change |
| 58 | Benitec Biopharma IncBNTC | — | 0.22% | $24.8M | 1.85M | $13.38 | $8.16 | 39.0% down | 3 qtrs | No change |
| 59 | Lenz Therapeutics IncLENZ | — | 0.21% | $23.7M | 4.18M | $5.68 | $3.65 | 35.8% down | 9+ qtrs | No change |
| 60 | Lexeo Therapeutics IncLXEO | — | 0.20% | $23.3M | 5M | $4.66 | $3.09 | 33.6% down | 3 qtrs | No change |
| 61 | Acrivon Therapeutics IncACRV | — | 0.19% | $21.8M | 12.23M | $1.78 | $1.48 | 16.9% down | 9+ qtrs | ▲ Added 47% |
| 62 | Altimmune IncALT | — | 0.17% | $19.8M | 6.5M | $3.04 | $1.55 | 49.2% down | 1 qtr | New |
| 63 | Karyopharm Therapeutics IncKPTI | — | 0.16% | $18.7M | 1.92M | $9.77 | $0.0174 | 99.8% down | 2 qtrs | No change |
| 64 | Bright Minds Biosciences IncDRUG | — | 0.16% | $18.6M | 265K | $70.20 | $20.86 | 70.3% down | 2 qtrs | No change |
| 65 | Avalo Therapeutics IncAVTX | — | 0.16% | $18.5M | 1M | $18.48 | $7.03 | 62.0% down | 8 qtrs | ▲ Added 51% |
| 66 | Onkure Therapeutics Inc-AOKUR | — | 0.16% | $18.2M | 4M | $4.56 | $2.56 | 44.0% down | 2 qtrs | No change |
| 67 | Faeth Therapeutics IncFTH | — | 0.16% | $18.1M | 722.02K | $25.00 | $8.73 | 65.1% down | 1 qtr | New |
| 68 | Aura Biosciences IncAURA | — | 0.15% | $17.8M | 2.5M | $7.10 | $7.14 | 0.6% up | 1 qtr | New |
| 69 | Sab Biotherapeutics IncSABS | — | 0.15% | $17.2M | 4.4M | $3.90 | $2.95 | 24.4% down | 4 qtrs | No change |
| 70 | Seaport Therapeutics IncSPTX | — | 0.13% | $15.2M | 700K | $21.72 | $18.27 | 15.9% down | 1 qtr | New |
| 71 | Palisade Bio IncPALI | — | 0.13% | $14.9M | 7.12M | $2.09 | $1.00 | 52.2% down | 3 qtrs | No change |
| 72 | Helix Acquisition CorpHLXC | — | 0.12% | $13.3M | 1.25M | $10.64 | $10.28 | 3.4% down | 2 qtrs | No change |
| 73 | Waystar Holding CorpWAY | Technology | 0.09% | $10.9M | 529.4K | $20.53 | $28.12 | 37.0% up | 3 qtrs | No change |
| 74 | Equillium IncEQ | — | 0.09% | $9.9M | 3.1M | $3.20 | $1.19 | 62.8% down | 2 qtrs | No change |
| 75 | Macrogenics IncMGNX | — | 0.08% | $8.6M | 1.86M | $4.62 | $2.10 | 54.7% down | 2 qtrs | No change |
| 76 | Perceptive Cap Solutionsno ticker on file | — | 0.07% | $8.2M | 750K | $10.88 | — | — | 9+ qtrs | No change |
| 77 | Adicet Bio IncACET | — | 0.07% | $8.1M | 932.62K | $8.64 | $2.77 | 68.0% down | 9+ qtrs | ▼ Reduced 21% |
| 78 | Newamsterdam Pharma Co NV-27no ticker on file · WTS | — | 0.06% | $7.1M | 333.33K | $21.37 | — | — | 9+ qtrs | No change |
| 79 | Corvus Pharmaceuticals IncCRVS | — | 0.06% | $6.7M | 450K | $14.94 | $10.40 | 30.4% down | 2 qtrs | No change |
| 80 | Rani Therapeutics Holdings-ARANI | — | 0.06% | $6.5M | 8.5M | $0.7604 | $0.5620 | 26.1% down | 3 qtrs | No change |
| 81 | Jatt II Acquisition CorpJATT | — | 0.05% | $5.7M | 500K | $11.36 | $10.20 | 10.2% down | 1 qtr | New |
| 82 | Amanat Acquisition CorpAMAN | — | 0.03% | $3.8M | 375K | $10.16 | $10.10 | 0.6% down | 1 qtr | New |
| 83 | Werewolf Therapeutics IncHOWL | — | 0.01% | $859.3K | 2.39M | $0.3599 | $0.9811 | 172.6% up | 9+ qtrs | ▼ Reduced 64% |
| 84 | Palatin Technologies IncPTN | — | 0.01% | $670.3K | 62.12K | $10.79 | $5.26 | 51.3% down | 3 qtrs | ▼ Reduced 11% |
Peter Kolchinsky latest buys (Q2 2026)
Peter Kolchinsky latest sells (Q2 2026)
Every buy and sell in Peter Kolchinsky's Q2 2026 13F →
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 42.6% | $4.9B | 8 |
| Technology | 0.09% | $10.9M | 1 |
| No sector on file | 57.3% | $6.6B | 75 |
8 quarterly filings on file for RA Capital Management, back to Q3 2024: reported value, position counts, and every buy and sell quarter by quarter.
Filing history →All Q2 2026 13F filings →Questions about Peter Kolchinsky's portfolio
What stocks does Peter Kolchinsky own?
According to RA Capital Management's 13F filing for Q2 2026, the largest of its 84 US-listed positions are ASND (23.8%), PBLS (6.9%), RYTM (6.4%), PCVX (5.8%) and SION (3.8%). A 13F shows long positions only, as of the quarter's end.
What is Peter Kolchinsky's largest holding?
ASND (Ascendis Pharma A/S), worth $2.7B at the end of Q2 2026, or 23.8% of the $11.5B RA Capital Management reported.
What did Peter Kolchinsky buy last quarter?
In Q2 2026, compared with the filing for Q1 2026, the largest purchases were PBLS (new position, $791.9M), COAG (new position, $286.8M), ABVX (new position, $150.9M), ORKA (new position, $148M) and ARTV (added, $78.6M).
What did Peter Kolchinsky sell last quarter?
In Q2 2026 the largest sales were DNTH (sold out, $219.2M), Nuvalent Inc (reduced, $159M), PRAX (sold out, $120.4M), SRPT (sold out, $84.9M) and EWTX (reduced, $82.7M), against the filing for Q1 2026.
How much is Peter Kolchinsky's portfolio worth?
RA Capital Management reported $11.5B in 84 US-listed positions for Q2 2026, valued at the quarter's end and filed on August 14, 2026. That is the 13F portfolio only: no cash, short positions or most shares listed outside the US.
When does Peter Kolchinsky file the next 13F?
The 13F for Q3 2026, the quarter ending September 30, 2026, was due by November 16, 2026: 45 days after the quarter ends, or the next business day. The latest filing on file here is for Q2 2026, filed on August 14, 2026.
Which sectors does Peter Kolchinsky own?
Health Care 42.6%, Technology 0.1% of the reported portfolio, with 57.3% in securities that have no sector on file here (funds, smaller companies, positions without a ticker).
How long has Peter Kolchinsky held these stocks?
Counting consecutive quarterly filings up to Q2 2026: ASND 9+, PBLS 1, RYTM 9+, PCVX 9+, SION 6, TYRA 9+. “9+” means the position is in every filing looked at, so it may go back further.
Learn
Cite this page
Funkfolio, “Peter Kolchinsky portfolio: RA Capital Management 13F holdings (Q2 2026)”, data as of 14 August 2026. https://funkfolio.com/gurus/peter-kolchinsky
Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending June 30, 2026.
Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Jun 30, 2026, filed Aug 14, 2026. “Last quarter” compares share counts with the filing for Mar 31, 2026. “Reported price” is the position's reported value divided by its shares — the price the filing implies for the period end. “Price now” is from Yahoo Finance and can be delayed 15 minutes or more; “since period end” sets the two side by side and is left blank where the reported price falls outside the stock's 52-week range, which points to a share split since. A split small enough to stay inside that range is not caught, and dividends are not counted. Sectors are those of the ranked companies on this site; funds, smaller companies and positions without a ticker have none. “Held” counts consecutive quarterly filings the position appears in, out of the 9 looked at. A buy or sell is sized as the shares moved at the price the filing implies; a position sold out at its value in the previous filing. Filings can be 45 days old when published; this is not a live portfolio and not advice.